Pharmaceutical industry – Page 7
-
BusinessArrayit chief convicted of fraud over blood testing
Mark Schena misrepresented the company’s value to investors and defrauded public and private insurers
-
OpinionAngela Russell: ‘We have to not be afraid of failing’
The medicinal chemist on thinking like a scientist and knowing where you want to go
-
WebinarEmpower your drug design & synthesis with vibrational circular dichroism (VCD)
Discover the advantage and benefits of VCD compared to other analytical techniques and learn how to develop a more efficient workflow
-
BusinessJ&J to phase out talc-based baby powder worldwide
In the face of thousands of lawsuits, firm will switch to cornstarch-based formulations
-
BusinessProtective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
-
OpinionWhy AlphaFold won’t revolutionise drug discovery
Protein structure prediction is a hard problem, but even harder ones remain
-
BusinessUK Reach costs stretch higher for industry
Government assessment suggests deadlines will be delayed and companies will pay billions for compliance data
-
NewsSoftware from Cambridge crystallographic experts could save pharma industry millions
Informatic tools will help drug formulators understand particle behaviour in their final product
-
OpinionMay cause side effects
The dose makes the poison, but understanding unwanted drug interactions is complicated
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
ArticleMaking quality the priority for fine and specialty chemicals suppliers
Precision measurements and data integrity are essential in pharma and cosmetics supply chains
-
BusinessCalifornia advances plans to make its own insulin
Governor commits $100 million to develop low-cost insulin and build manufacturing facility to strengthen drug’s supply chain
-
BusinessSecond Theranos executive convicted of fraud
Blood testing startup president Ramesh ‘Sunny’ Balwani defrauded both investors and patients
-
BusinessNovartis cutting up to 8000 jobs
Restructure splits commercial activities geographically instead of by treatment area
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
BusinessSoapbark branches out to fill essential role in vaccine recipes
The soapbark tree has long been used in traditional medicines, but is now coveted for some of our newest vaccines
-
FeatureUsing genetics to personalise prescriptions
We’ve known for a long time that different people respond to certain drugs to very different extents, but now cheap DNA testing could make these disparities a thing of the past, as Ian Le Guillou reports
-
OpinionCatalogues of complexity
The tangled web of fine chemicals supply frequently throws up surprises
-
BusinessWhat is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment
-
FeatureThe incredible antibodies of sharks, llamas and camels
Sharks and llamas share a strange quirk of their immune systems. Hayley Bennett finds out how their ‘nanobodies’ could help us tackle Covid and a host of other diseases